On November 25, 2024 PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, reported a slate of nine new abstracts exploring the use of ropeginterferon alfa-2b-njft, known in market as BESREMi, will be presented during the 66th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition in San Diego, CA (Press release, PharmaEssentia, NOV 25, 2024, View Source [SID1234648637]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentations at ASH (Free ASH Whitepaper) include a quality-of-life evaluation for patients with polycythemia vera (PV) or essential thrombocythemia (ET) and treated with ropeginterferon alfa-2b compared to other best available therapies; identifying the efficacy and safety of ropeginterferon alfa-2b in low-risk PV patients and the potential of an AI-powered approach to discovering potential new indications for ropeginterferon alfa-2b.

"With new clinical findings, AI-powered results and real-world analyses, we are excited to continue to advance our knowledge on the potential of ropeginterferon alfa-2b in treating chronic and life-threatening myeloproliferative neoplasms," said Ko-Chung Lin, Ph.D., Founder and CEO of PharmaEssentia. "PharmaEssentia maintains its commitment to educating providers and patients to make informed decisions to improve care and outcomes for people living with myeloproliferative neoplasms such as PV and ET."

Ropeginterferon Alfa-2b presentations at ASH (Free ASH Whitepaper) include:

Ropeginterferon Alfa-2b Induces Apoptosis and Differentiation of Leukemia Stem Cells and Separates GVL Effects from GVHD after Allogeneic Hematopoietic Cell Transplantation
Oral Presentation Abstract #902: Monday, December 9, 2024, 2:45-4:15 PM PT
Quality of Life Evaluation for Patients on Ropeginterferon Alpha-2b Versus Other Best Available Therapies
Poster Presentation Abstract #1791: Saturday, December 7, 2024, 5:30-7:30 PM PT
Ropeginterferon in Low-risk Patients with Polycythemia Vera
Poster Presentation Abstract #1799: Saturday, December 7, 2024, 5:30-7:30 PM PT
HOPE-PMF: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Assess Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Early/Lower-Risk Primary Myelofibrosis
Poster Presentation Abstract #3191.1: Sunday, December 8, 2024, 6:00-8:00 PM PT
Predicting Molecular Response through Half Reduction of Neutrophil-to-Lymphocyte ratio (NLR) in Polycythemia Vera Treatment with Ropeginterferon
Poster Presentation Abstract #3170: Sunday, December 8, 2024, 6:00-8:00 PM PT
Remarkable molecular response in Chinese PV patients treated with Ropeginterferon alfa-2b
Poster Presentation Abstract #4562: Monday, December 9, 2024, 6:00-8:00 PM PT
Ropeginterferon Alfa-2b (ROPEG) and Peginterferon Alfa-2a (PEG) at Low Dose with Response-Based Titration (LDRT) Have Comparable Efficacy and Tolerability in Polycythemia Vera (PV)
Poster Presentation Abstract #4568: Monday, December 9, 2024, 6:00-8:00 PM PT
Accelerating Drug Discovery: AI-Powered Indication Exploration for Ropeginterferon Alfa-2b
Poster Presentation Abstract #4982: Monday, December 9, 2024, 6:00-8:00 PM PT
Treatment Patterns of Ropeginterferon Alfa-2b-njft in the real-world setting
Poster Presentation Abstract #5184: Monday, December 9, 2024, 6:00-8:00 PM PT